Effect of Instrument-assisted Soft Tissue Mobilization on Functional and Cognitive Abilities in Elderly
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age65-75
SponsorCairo University
About this trial
PURPOSE: To determine the effect of Instrument-assisted soft tissue mobilization on functional and cognitive abilities in elderly.
BACKGROUND: There is an increased interest in health care with growth of the older population.
Instrument-Assisted Soft Tissue Mobilization (IASTM) is a manual therapy technique using specially designed tools to apply pressure and mobilize soft tissues. It has gained attention as a non-invasive intervention that can aid in improving musculoskeletal health and overall function, especially in older adults. Given the aging population and the rise in age-related functional and cognitive decline, there is a pressing need for effective strategies to enhance quality of life in this demographic.
In the elderly, musculoskeletal issues, such as reduced muscle flexibility, joint stiffness, and soft tissue restrictions, are common and can severely impact physical function. IASTM has been shown to increase tissue perfusion, reduce fascial restrictions, and improve joint mobility. These effects are critical in countering age-related declines in mobility, balance, and overall physical functionality, ultimately promoting greater independence and reducing fall risk. Improved physical function through IASTM may also influence cognitive health positively, as increased physical activity and mobility are linked to better cognitive outcomes in the elderly.
HYPOTHESES: There will be no significant effect of Instrument-assisted soft tissue mobilization on functional and cognitive abilities in elderly.
RESEARCH QUESTION: Does instrument-assisted soft tissue mobilization is effective on functional and cognitive abilities in elderly?
Eligibility criteria
This trial accepts healthy volunteersQualifiers
60 elderly subjects aged range from 65-75 years old will participant in the study from both genders.
had cognitive abilities to understand explanations and instructions
did not take any medication that can affect their balance.
Disqualifiers
They neither had sever musculoskeletal disorders
Nor neurological damage related to balance (dizziness, vestibular dysfunction)
Nor orthostatic hypotension
Nor health risk factors.
Trial design
Design model
Parallel
Treatments tested in this trial
Instrument-assisted soft tissue mobilization
DeviceIASTM will be delivered using stainless-steel instruments with beveled edges, applied to the target muscle groups for approximately 20 minutes per session, two times per week, over four weeks. A licensed physical therapist trained in IASTM will perform the procedure. Lubricant will be applied to the skin, and strokes will be delivered in multiple directions with pressure adapted to patient tolerance.
Traditional physical therapy
BehavioralThe control group will receive a traditional physical therapy program focusing on strength, balance, flexibility, and functional mobility training, combined with simple cognitive stimulation tasks. Sessions will last 30 minutes, two times per week, for four weeks, supervised by a licensed physical therapist.
Treatment groups
60 Participants
are divided into 2 treatment groupsGroup A: IASTM on calf muscle bilaterally plus conventional treatment (strengthening and stretching exerciseExperimental treatment 2 interventions
Group B: control group, will receive conventional treatmentActive comparator 1 intervention
Trial outcomes
Primary outcomes
1
Change in Short Physical Performance Battery (SPPB) score
Mean change in SPPB total score (0-12; higher = better physical function) from baseline to end of intervention. The SPPB includes standing balance, 4-m gait speed, and five-times-sit-to-stand.
Time frame
Baseline and 4 weeks (end of treatment).Secondary outcomes
1
Change in Montreal Cognitive Assessment (MoCA) score
Mean change in MoCA total score (0-30; higher = better cognition) from baseline to end of intervention and at follow-up.
Time frame
Baseline and 4 weeks (end of treatment).Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov